In this article you will see that autism, considered virtually an incurable disease, may well be nothing more than mercury poisoning -- and Life Glow Plus oral chelation should handle this completely.
14 Commerce
Drive
Cranford, NJ
07016
April 3, 2000
Autism is a neurodevelopmental syndrome
characterized by impairments in social relatedness, language, and communication,
a need for routine and sameness, abnormal movements, and sensory dysfunction.
Mercury is a toxic metal that can exist as a pure element or in a variety
of inorganic and organic forms and can cause immune, sensory, neurological,
motor, and other behavioral dysfunctions.
The characteristics of autism and mercury poisoning, derived from a review of medical literature, have been found, upon comparison, to be strikingly similar. The characteristics of both disorders are summarized in the following table and fully elucidated in the body of this document. The parallels between the two diseases are so close that it would be unreasonable to assume that the similarities occur by chance.
We claim that autism is a form of mercury poisoning, based on similarities of characteristics and on the known exposure to mercury of the majority of US children. The exposure route is childhood vaccines, most of which contain thimerosal, a preservative comprised of 50% ethylmercury by weight. The amount of mercury a typical child under two years receives from vaccinations equates to 237.5 micrograms, or 3.53 x 1017 molecules (353,000,000,000,000,000 molecules), most of which is not excreted and goes directly to the brain. The amount is known to exceed Federal safety standards, but is still considered a “low” level, such that only a small percentage of exposed individuals will exhibit signs of toxicity. Affected individuals are those genetically prone to mercury sensitivity, which is consistent with the observed high heritability rate of autism. Furthermore, the timing of mercury exposure via vaccines coincides with the emergence of autistic symptoms. Moreover, mercury has been detected in urine, hair, and blood samples from autistic children, and parental reports, though limited at this date, indicate significant improvement in symptoms with administration of standard heavy metal chelators. Thus, the four agreed-upon criteria used by clinicians to diagnose mercury poisoning – i.e., observable symptoms, known exposure at the time of symptom onset, detectable levels in biologic samples, and improvement with chelation - have been met for autism.
The phenotypic expression of mercury poisoning varies by a host of factors – including type of mercury given, method of administration, rate and level of dose, individual genotype, and age of patient – so that each variation in factors has created in the past a slightly different manifestation of the disease – Mad Hatter’s disease, Minamata disease, and acrodynia, for example. The pathology arising from the set of mercury-related variables involved in autism – intermittent bolus doses of ethylmercury injected into genetically susceptible infants and toddlers – has never been reported before in medical literature. Thus we argue that autism represents a unique form of mercury poisoning not heretofore described. Our findings have widespread implications for the affected population of autistic individuals, for other unexplained disorders with symptoms similar to heavy metal intoxication, and for childhood vaccination programs.
of Autism &
Mercury Poisoning
|
|
Mercury Poisoning
|
Autism |
|
Psychiatric |
Social deficits,
shyness, social withdrawal |
Social deficits,
social withdrawal, shyness |
|
Disturbances |
Depression, mood
swings; mask face |
Depressive traits,
mood swings; flat affect |
|
|
Anxiety |
Anxiety |
|
|
Schizoid tendencies,
OCD traits |
Schizophrenic &
OCD traits; repetitiveness |
|
|
Lacks eye contact,
hesitant to engage others |
Lack of eye contact,
avoids conversation |
|
|
Irrational fears |
Irrational fears |
|
|
Irritability,
aggression, temper tantrums |
Irritability,
aggression, temper tantrums |
|
|
Impaired face
recognition |
Impaired face
recognition |
|
|
|
|
|
Speech, |
Loss of speech,
failure to develop speech |
Delayed language,
failure to develop speech |
|
Language
& |
Dysarthria;
articulation problems |
Dysarthria;
articulation problems |
|
Hearing
|
Speech
comprehension deficits |
Speech
comprehension deficits |
|
Deficits |
Verbalizing & word
retrieval problems |
Echolalia; word use
& pragmatic errors |
|
|
Sound sensitivity |
Sound sensitivity |
|
|
Hearing loss; deafness
in very high doses |
Mild to profound
hearing loss |
|
|
Poor performance on
language IQ tests |
Poor performance on
verbal IQ tests |
|
|
|
|
|
Sensory
|
Abnormal sensation in
mouth & extremities |
Abnormal sensation in
mouth & extremities |
|
Abnormalities |
Sound sensitivity |
Sound sensitivity |
|
|
Abnormal touch
sensations; touch aversion |
Abnormal touch
sensations; touch aversion |
|
|
Vestibular
abnormalities |
Vestibular
abnormalities |
|
|
|
|
|
Motor
Disorders |
Involuntary jerking
movements - arm flapping, ankle jerks, myoclonal jerks, choreiform
movements, circling, rocking |
Stereotyped movements
- arm flapping, jumping, circling, spinning, rocking; myoclonal jerks;
choreiform movements |
|
|
Deficits in eye-hand
coordination; limb apraxia; intention tremors |
Poor eye-hand
coordination; limb apraxia; problems with intentional movements |
|
|
Gait impairment;
ataxia – from incoordination & clumsiness to inability to walk,
stand, or sit; loss of motor control |
Abnormal
gait and posture, clumsiness and incoordination; difficulties sitting,
lying, crawling, and walking |
|
|
Difficulty in chewing
or swallowing |
Difficulty chewing or
swallowing |
|
|
Unusual postures |
Unusual postures |
|
|
|
|
|
Cognitive
Impairments |
Borderline
intelligence, mental retardation - some cases reversible |
Borderline
intelligence, mental retardation - sometimes "recovered" |
|
|
Poor concentration,
attention, response inhibition |
Poor
concentration, attention, shifting attention |
|
|
Uneven performance on
IQ subtests |
Uneven performance on
IQ subtests |
|
|
Verbal IQ higher than
performance IQ |
Verbal
IQ higher than performance IQ |
|
|
Poor short term,
verbal, & auditory memory |
Poor short term,
auditory & verbal memory |
|
|
Poor visual and
perceptual motor skills, impairment in simple reaction time |
Poor visual and
perceptual motor skills, lower performance on timed tests |
|
|
Difficulty carrying
out complex commands |
Difficulty carrying
out multiple commands |
|
|
Alexia (inability to
comprehend the meaning of written words) |
Hyperlexia (ability to
decode words while lacking word comprehension) |
|
|
Deficits in
understanding abstract ideas & symbolism; degeneration of higher
mental powers |
Deficits in abstract
thinking & symbolism, understanding other’s mental states,
sequencing, planning & organizing |
(ii)
Unusual |
Stereotyped sniffing
(rats) |
Stereotyped,
repetitive behaviors |
|
Behaviors |
ADHD traits |
ADHD traits |
|
|
Agitation, unprovoked
crying, grimacing, staring spells |
Agitation, unprovoked
crying, grimacing, staring spells |
|
|
Sleep difficulties |
Sleep difficulties |
|
|
Eating disorders,
feeding problems |
Eating disorders,
feeding problems |
|
|
Self injurious
behavior, e.g. head banging |
Self injurious
behavior, e.g. head banging |
|
|
|
|
|
Visual |
Poor eye contact,
impaired visual fixation |
Poor eye contact,
problems in joint attention |
|
Impairments |
“Visual
impairments,” blindness, near-sightedness, decreased visual acuity |
“Visual
impairments”; inaccurate/slow saccades; decreased rod functioning |
|
|
Light sensitivity,
photophobia |
Over-sensitivity to
light |
|
|
Blurred or hazy vision |
Blurred vision |
|
|
Constricted visual
fields |
Not described |
|
|
|
|
|
Physical
Disturbances |
Increase in cerebral
palsy; hyper- or hypo-tonia; abnormal reflexes; decreased muscle strength,
especially upper body; incontinence; problems chewing, swallowing,
salivating |
Increase in cerebral
palsy; hyper- or hypotonia; decreased muscle strength, especially upper
body; incontinence; problems chewing and swallowing |
|
|
Rashes, dermatitis/dry
skin, itching; burning |
Rashes, dermatitis,
eczema, itching |
|
|
Autonomic
disturbance: excessive
sweating, poor circulation, elevated heart rate |
Autonomic disturbance:
unusual sweating, poor circulation, elevated heart rate |
|
|
|
|
|
Gastro-intestinal |
Gastroenteritis,
diarrhea; abdominal pain, constipation, “colitis” |
Diarrhea,
constipation, gaseousness, abdominal discomfort, colitis |
|
Disturbances |
Anorexia, weight loss,
nausea, poor appetite |
Anorexia; feeding
problems/vomiting |
|
|
Lesions of ileum &
colon; increases gut permeability |
Leaky gut syndrome |
|
|
Inhibits dipeptidyl
peptidase IV, which cleaves casomorphin |
Inadequate
endopeptidase enzymes needed for breakdown of casein & gluten |
|
|
|
|
|
Abnormal
Biochemistry |
Ties up -SH groups;
blocks sulfate transporter in intestines, kidneys |
Low sulfate levels |
|
|
Has special affinity
for purines & pyrimidines |
Purine
& pyrimidine metabolism errors lead to autistic features |
|
|
Reduces availability
of glutathione, needed in cells & liver to detoxify heavy metals |
Low levels of
glutathione; decreased ability of liver to detoxify heavy metals |
|
|
Causes significant
reduction in glutathione
peroxidase and glutathione reductase |
Abnormal glutathione
peroxidase activities in erythrocytes |
|
|
Disrupts mitochondrial
activities, especially in brain |
Mitochondrial
dysfunction, especially in brain |
|
|
|
|
|
Immune
Dysfunction |
Sensitivity due to
allergic or autoimmune reactions; sensitive individuals more likely to
have allergies, asthma, autoimmune-like symptoms, especially
rheumatoid-like ones |
More likely to have
allergies and asthma; familial presence of autoimmune diseases, especially
rheumatoid arthritis; IgA deficiencies |
|
|
Can produce an immune
response in CNS |
On-going immune
response in CNS |
|
|
Causes brain/MBP
autoantibodies |
Brain/MBP
autoantibodies present |
|
|
Causes overproduction
of Th2 subset; kills/inhibits lymphocytes, T-cells, and monocytes;
decreases NK T-cell activity; induces or suppresses IFNg & IL-2 |
Skewed immune-cell
subset in the Th2 direction; decreased responses to T-cell mitogens;
reduced NK T-cell function; increased IFNg & IL-12 |
|
CNS
Structural Pathology |
Selectively targets
brain areas unable to detoxify or reduce Hg-induced oxidative stress |
Specific areas of
brain pathology; many functions spared |
|
|
Damage to Purkinje and
granular cells |
Damage to Purkinje and
granular cells |
|
|
Accummulates in
amygdala and hippocampus |
Pathology in amygdala
and hippocampus |
|
|
Causes abnormal
neuronal cytoarchitecture; disrupts neuronal migration & cell
division; reduces NCAMs |
Neuronal
disorganization; increased neuronal cell replication, increased glial
cells; depressed expression of NCAMs |
|
|
Progressive
microcephaly |
Progressive
microcephaly and macrocephaly |
|
|
Brain stem defects in
some cases |
Brain stem defects in
some cases |
|
|
|
|
|
Abnormalities
in Neuro-chemistry |
Prevents presynaptic
serotonin release & inhibits serotonin transport; causes calcium
disruptions |
Decreased serotonin
synthesis in children; abnormal
calcium metabolism |
|
|
Alters dopamine
systems; peroxidine deficiency in rats resembles mercurialism in humans |
Possibly high or low
dopamine levels; positive response to peroxidine (lowers dopamine levels) |
|
|
Elevates epinephrine
& norepinephrine levels by blocking enzyme that degrades epinephrine |
Elevated
norepinephrine and epinephrine |
|
|
Elevates glutamate |
Elevated glutamate and
aspartate |
|
|
Leads to cortical
acetylcholine deficiency; increases muscarinic receptor density in
hippocampus & cerebellum |
Cortical acetylcholine
deficiency; reduced muscarinic receptor binding in hippocampus |
|
|
Causes demyelating
neuropathy |
Demyelation in brain |
|
|
|
|
|
EEG
Abnormalities/ |
Causes abnormal EEGs,
epileptiform activity |
Abnormal EEGs,
epileptiform activity |
|
Epilepsy |
Causes seizures,
convulsions |
Seizures; epilepsy |
|
|
Causes subtle, low
amplitude seizure activity |
Subtle, low amplitude
seizure activities |
|
|
|
|
|
Population |
Effects more males
than females |
Male:female ratio
estimated at 4:1 |
|
Characteristics |
At low doses, only
affects those genetically susceptible |
High heritability -
concordance for MZ twins is 90% |
|
|
First added to
childhood vaccines in 1930s |
First
"discovered" among children born in 1930s |
|
|
Exposure levels
steadily increased since 1930s with rate of vaccination, number of
vaccines |
Prevalence of autism
has steadily increased from 1 in 2000 (1940s) to 1 in 500 (1990s) |
|
|
Exposure occurs at 0 -
15 months; clinical silent stage means symptom emergence delayed; symptoms
emerge gradually, starting with movement & sensation |
Symptoms emerge from 4
months to 2 years old; symptoms emerge gradually, starting with movement
& sensation |
If you missed it, you can go to either a SHORT explanation of the whole story, or a detailed explanation on ONE PAGE. On this page you are getting more detail on one part of the story, but on either of those pages you can get the broad picture. Don't miss reading one of them. You can actually spend many hours on this web site, depending on the depth of research and reading you want to do. There are an amazing 4,000 pages here -- more information on these general subjects than almost all other web sites combined! At some point along the way you will probably say, "Karl's crazy," and leave never to return to this site, or you will say "I want to try some of that oral chelation formula he writes about!"
|
I promise to answer your message -- click here to send me a personal message
|
SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren. You can view more than 50 back issues of this publication by clicking here. The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter. It is automatically published on the Tuesday night just before the first Wednesday of every month. You can subscribe to this free monthly electronic letter by entering your eMail address and name below. You will then automatically receive a request for confirmation, sent to whatever address you have entered. If you do NOT receive this confirmation request, then you will not be subscribed. There may have been an error with your address and you should resubmit. The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription. When you receive this confirmation request you must reply to it, or your subscription will not become active. No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL: You can remove yourself from the subscription list in several different ways. Click here to read about this entire newsletter system. Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list. If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed. Thus, no one else can unsubscribe you, from some other computer, without your knowledge. But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message: When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions. Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US. You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites. Vibrant Life normally ships the same day we get an order. There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vi
